Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Neoplasms 1Myeloproliferative Disorders 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1

Interventions

venetoclax 1obinutuzumab 1liposomal doxorubicin 1duvelisib 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1CA-4948 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × CA-4948 × Other hematologic neoplasm × Clear all
NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Curis, Inc.

Phase 1/2 Suspended
366 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡